Correction
Published on 27 Nov 2024
Corrigendum: Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1472829
Type at least 3 characters
1,011 articles
Articles
Correction
Accepted on 26 Nov 2024
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of Lenvatinib in hepatocarcinoma cells.
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1532291
Case Report
Accepted on 26 Nov 2024
Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: A case report and literature review
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1453259
Correction
Published on 25 Nov 2024
Corrigendum: Long non-coding RNA SNHG1 regulates the Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1501882
- 126 views
Review
Published on 25 Nov 2024
Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1481777
- 150 views
Review
Accepted on 22 Nov 2024
The Antitumor Mechanisms of Glabridin and Drug Delivery Strategies for Enhancing Its Bioavailability
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1506588
Case Report
Published on 20 Nov 2024
Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1458990
- 208 views
Original Research
Accepted on 19 Nov 2024
Cutaneous adverse events due to Checkpoint inhibitors – A retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022.
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1485594
Editorial
Accepted on 18 Nov 2024
Editorial: Photodynamic Therapy: Challenges and Innovations for Treating Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1526550
Editorial
Accepted on 18 Nov 2024
Editorial: DNA Methylation in Cancer Therapy: Therapeutic Targets and Molecular Mechanism
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1508214
Correction
Accepted on 18 Nov 2024
Corrigendum: Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1515205
Review
Published on 12 Nov 2024
Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1445794
- 250 views
Original Research
Published on 08 Nov 2024
Mechanism of luteolin against non-small-cell lung cancer: a study based on network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1471109
- 368 views
Original Research
Accepted on 30 Oct 2024
Pembrolizumab versus Sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1422039
Correction
Published on 28 Oct 2024
Corrigendum: Dietary polyphenols, resveratrol and pterostilbene exhibit antitumor activity on an HPV E6-positive cervical cancer model: an in vitro and in vivo analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1483410
- 254 views
Review
Published on 23 Oct 2024
Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2024.1438040
- 758 views